Share Your Story – Sativex and Medical Cannabis
Sativex, or Cannabidiol with tetrahydrocannabinol, is an add-on treatment approved by Medsafe for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis (MS). It is indicated for people who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial […]
Pharmax Sativex
In December 2023, Pharmac proposed to decline funding for inactive applications, this included an application to fund Sativex for MS spasticity. MSNZ has written to the Pharmac Board to ask that this application remain live and we be permitted to present more evidence regarding the patient’s need. Sativex is currently unfunded and costs approximately $300 […]